AstraZeneca will push the pill, elecoglipron, into a comprehensive late-stage program that will test the drug as a monotherapy, as part of a combination regimen and for several indications.
As the field grows rapidly, companies are luring people from other nuclear industries and tapping the expanding educational talent pipeline, but are constrained by a steep learning curve and the value of real-world experience.
The Internal Revenue Service is adding capabilities to the online Tax Pro Account, allowing firms to specify which staff members are authorized with CAF access.
Users can log in to free apps like Google Gemini or ChatGPT and create realistic-looking, fraudulent documents — such as fake receipts or invoices — in seconds.
Big Four KPMG announced that the employees and founders of AI development platform PrivateBlok will be joining the firm to further scale its AI capacities.
The deal gets Lilly access to Orna’s in vivo CAR T technology. The biotech’s lead asset, which has yet to start clinical testing, is focused on B cell–driven autoimmune diseases.